← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 2.0% below its 1-year high (as of 2026-09-17). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 8.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Owner-earnings 10-yr IRR 10–30 points over Treasuries, yield ≤ 25% · bought the day of the annual report, held 12 months
Could be luck Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +2.9 pts (823 entries, 255 companies, could be luck). 47% of entries beat the S&P; 18% beat it by 30 points or more; 27% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +1.2 pts.
+2.9 ptsvs S&P, average
47%beat the S&P
18%up 30+ pts vs S&P
27%down 20+ pts vs S&P
+6.0 ptsvs small caps, 12 mo
−14.6 pts 2024worst year to buy ?
1.8luck check ?
Does the holding period matter?3 mo: −0.5 pts 47% beat6 mo: +0.1 pts 45% beat12 mo: +2.9 pts 47% beat24 mo: +3.3 pts 42% beat3 yr, per yr: −0.9 pts 39% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today686+1.9 pts t 1.2+5.3 pts
Sell-off (S&P ≥10% off high)137+7.9 pts t 1.4+9.6 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing255+0.9 pts t 0.4−5.1 pts
Retail & consumer106+10.5 pts t 1.9+1.9 pts
Services79−3.2 pts t -0.5−1.9 pts
Energy69+3.1 pts t 0.5−4.9 pts
Other61−4.4 pts t -0.8−3.3 pts
Tech hardware & semis58−2.8 pts t -0.6−1.4 pts
Finance & real estate46+5.9 pts t 1.5+6.8 pts
Biotech & pharma28−5.0 pts t -0.7−4.3 pts

Holds up out of sample? Before 2018: +5.1 pts (n 291, t 2.3). From 2018: +1.7 pts (n 532, t 0.8). Same sign in both halves.

Year201120122013201420152016201720182019202020212022202320242025
vs S&P−11 pts+5 pts+6 pts−5 pts−4 pts+17 pts+8 pts−10 pts−14 pts+46 pts+8 pts+8 pts−14 pts−15 pts+3 pts
n12943515669425362725676876957

Read the research behind this screen: Ranking companies as equity bonds: the top fifth beats the bottom fifth by a wide margin → · Test your own combination in the Screen Lab →

Same definitions as the table: coupon = 3-yr average owner earnings, growth capped, 15× exit. Historical IRR uses a 5-yr revenue CAGR as the growth proxy where the DCF rate is not available point-in-time. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

IIF
MORGAN STANLEY INDIA INVESTMENT FUND, INC.
Below Treasuries
Unknown
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IIM
Invesco Value Municipal Income Trust
Below Treasuries
Unknown
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IKT
Inhibikase Therapeutics, Inc.
Below Treasuries
Healthcare Risk 40 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +107.3%/yr vs model +2.0% · above model
ILAG
Intelligent Living Application Group Inc.
Below Treasuries
Consumer Cyclical Risk 33 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +11.0%/yr vs model +2.0% · above model
ILLR
Triller Group Inc.
Below Treasuries
Financial Services Risk 46 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +56.6%/yr vs model +17.2% · above model
ILLU
Illumination Acquisition Corp. I
Below Treasuries
Financial Services Risk 36 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
ILMN
ILLUMINA, INC.
Below Treasuries
Healthcare Risk 42 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +17.7%/yr vs model +3.0% · above model
ILPT
Industrial Logistics Properties Trust
Below Treasuries
Financial Services Risk 33 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IMA
ImageneBio, Inc.
Below Treasuries
Healthcare Risk 35 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +53.3%/yr vs model +2.0% · above model
IMCC
IM Cannabis Corp.
Below Treasuries
Healthcare Risk 49 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IMDX
Insight Molecular Diagnostics Inc.
Below Treasuries
Healthcare Risk 35 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +51.7%/yr vs model +16.5% · above model
IMKTA
INGLES MARKETS INC
Below Treasuries
Consumer Defensive
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IMMP
IMMUTEP Ltd
Below Treasuries
Healthcare Risk 52 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IMMR
IMMERSION CORP
Below Treasuries
Technology Risk 55 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies -50.0%/yr vs model +50.0% · below model
IMMX
Immix Biopharma, Inc.
Below Treasuries
Healthcare Risk 27 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IMNM
Immunome Inc.
Below Treasuries
Healthcare Risk 35 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +103.6%/yr vs model +15.0% · above model
IMNN
Imunon, Inc.
Below Treasuries
Healthcare Risk 43 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +11.3%/yr vs model +15.0% · below model
IMO
IMPERIAL OIL LTD
Below Treasuries
Energy Risk 52 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IMOS
CHIPMOS TECHNOLOGIES INC
Below Treasuries
Technology Risk 27 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IMRN
Immuron Ltd
Below Treasuries
Healthcare Risk 40 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IMRX
Immuneering Corp
Below Treasuries
Healthcare Risk 29 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +93.3%/yr vs model +15.0% · above model
IMSR
Terrestrial Energy Inc. /DE/
Below Treasuries
Industrials Risk 42 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +138.2%/yr vs model +15.0% · above model
IMTE
Integrated Media Technology Ltd
Below Treasuries
Technology Risk 46 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IMTX
Immatics N.V.
Below Treasuries
Healthcare Risk 32 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IMUX
IMMUNIC, INC.
Below Treasuries
Healthcare Risk 36 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IMVT
Immunovant, Inc.
Below Treasuries
Healthcare Risk 42 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
INAB
IN8BIO, INC.
Below Treasuries
Healthcare Risk 33 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
INAC
Indigo Acquisition Corp.
Below Treasuries
Financial Services Risk 34 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
INACR
Indigo Acquisition Corp.
Below Treasuries
Financial Services Risk 43 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
INBK
First Internet Bancorp
Below Treasuries
Financial Services Risk 55 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +42.8%/yr vs model +15.0% · above model
INBX
Inhibrx Biosciences, Inc.
Below Treasuries
Healthcare Risk 68 · High
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +150.0%/yr vs model +2.0% · above model
INCR
Intercure Ltd.
Below Treasuries
Healthcare Risk 44 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
INDO
Indonesia Energy Corp Ltd
Below Treasuries
Energy Risk 26 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +39.1%/yr vs model +0.0% · above model
INDP
Indaptus Therapeutics, Inc.
Below Treasuries
Healthcare Risk 44 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
INDV
Indivior Pharmaceuticals, Inc.
Below Treasuries
Healthcare Risk 35 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies -5.4%/yr vs model +15.0% · below model
INFQ
Infleqtion, Inc.
Below Treasuries
Technology Risk 39 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
INFY
Infosys Ltd
Below Treasuries
Technology Risk 46 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
ING
ING GROEP NV
Below Treasuries
Financial Services Risk 43 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
INHD
INNO HOLDINGS INC.
Below Treasuries
Basic Materials Risk 34 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +42.4%/yr vs model +0.0% · above model
INKT
MiNK Therapeutics, Inc.
Below Treasuries
Healthcare Risk 42 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
INMB
Inmune Bio, Inc.
Below Treasuries
Healthcare Risk 42 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +123.8%/yr vs model +2.0% · above model
INO
INOVIO PHARMACEUTICALS, INC.
Below Treasuries
Healthcare Risk 31 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +101.8%/yr vs model +2.0% · above model
INTC
INTEL CORP
Below Treasuries
Technology Risk 27 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +41.7%/yr vs model +0.0% · above model
INTR
Inter & Co, Inc.
Below Treasuries
Financial Services Risk 40 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
INTS
INTENSITY THERAPEUTICS, INC.
Below Treasuries
Healthcare Risk 33 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
INTZ
INTRUSION INC
Below Treasuries
Technology Risk 37 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +41.8%/yr vs model +2.0% · above model
INV
Innventure, Inc.
Below Treasuries
Financial Services Risk 37 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +49.2%/yr vs model +50.0% · in line
INVZ
Innoviz Technologies Ltd.
Below Treasuries
Consumer Cyclical Risk 31 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +23.4%/yr vs model +8.0% · above model
IONQ
IonQ, Inc.
Below Treasuries
Technology Risk 37 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +55.1%/yr vs model +50.0% · above model
IONR
ioneer Ltd
Below Treasuries
Basic Materials Risk 37 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IONS
IONIS PHARMACEUTICALS INC
Below Treasuries
Healthcare Risk 45 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +9.6%/yr vs model +3.9% · above model
IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Below Treasuries
Healthcare Risk 34 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies -50.0%/yr vs model +15.0% · below model
IPB
MERRILL LYNCH DEPOSITOR INC INDEXPLUS TRUST SERIES 2003-1
Below Treasuries
Financial Services
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IPCX
Inflection Point Acquisition Corp. III
Below Treasuries
Financial Services
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IPCXR
Inflection Point Acquisition Corp. III
Below Treasuries
Financial Services
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IPEX
Inflection Point Acquisition Corp. V
Below Treasuries
Financial Services
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IPEXR
Inflection Point Acquisition Corp. V
Below Treasuries
Financial Services
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IPFX
Inflection Point Acquisition Corp. VI
Below Treasuries
Financial Services
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IPHA
Innate Pharma SA
Below Treasuries
Healthcare Risk 54 · Elevated
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
IPM
INTELLIGENT PROTECTION MANAGEMENT CORP.
Below Treasuries
Technology Risk 27 · Moderate
Yield0.0%
Growth used0.0%
10-yr IRR0.0%
· 0 yrs positive P/IV —
Market implies +19.7%/yr vs model -1.1% · above model